Showing Page:
1/1
© 2021 Chamberlain University. All Rights Reserved
Medication Name and Type
Gloperba (Antimitotic)
Drug Class
Antigout Agents
Expected Pharmacological Mechanism of
Action (How it Works)
Interferes with the capabilities of WBCs in
starting up and perpetuating the
inflammatory reaction to monosodium
urate crystals.
Therapeutic Uses (Indications)
It helps to treat acute attacks of gouty
arthritis. Prophylaxis.
Contraindications
Contraindicated in hypersensitivity; Could
lead to renal and hepatic impairment. Use
of P-glycoprotein inhibitors or strong
CYP3A4 inhibitors in patients with renal or
hepatic impairment.
Complications
Derm: alopecia. Gi: diarrhea, nausea,
vomiting, abdominal pain. Hemat:
agranulocytosis, aplastic anemia,
leukopenia, thrombocytopenia. Neuro:
peripheral neuritis.
Interactions
Drug-Drug: Concurrent use of strong
CYP3A4 inhibitors, including atazanavir,
clarithromycin, etc. and risk of toxicity;
colchicine dose in patients with normal
renal or hepatic function; concurrent use in
patients with renal or hepatic impairment
is contraindicated.
Medication Administration (Dose and
Route)
PO (Adults): 1.2 mg initially, then 0.6 mg 1
hr later (maximum dose of 1.8 mg in 1 hr);
Nursing Interventions
Monitor intake and output ratios. Fluids
should be encouraged to promote a urinary
output of at least 2000 mL/day.
Client Education
Instruct patient to take colchicine as
directed. Review medication administration
schedule. Take missed doses as soon as
remembered unless almost time for next
dose.
Evaluation of Medication Effectiveness
Decrease in pain and swelling in affected joints
within 12 hr. Relief of symptoms within 24 48
hr. Prevention of acute gout attacks. Reduced
number of attacks of familial Mediterranean
fever.

Unformatted Attachment Preview

Expected Pharmacological Mechanism of Action (How it Works) Contraindications Contraindicated in hypersensitivity; Could lead to renal and hepatic impairment. Use of P-glycoprotein inhibitors or strong CYP3A4 inhibitors in patients with renal or hepatic impairment. Interferes with the capabilities of WBCs in starting up and perpetuating the inflammatory reaction to monosodium urate crystals. Therapeutic Uses (Indications) It helps to treat acute attacks of gouty arthritis. Prophylaxis. Medication Administration (Dose and Route) Medication Name and Type Complications PO (Adults): 1.2 mg initially, then 0.6 mg 1 hr later (maximum dose of 1.8 mg in 1 hr); Gloperba (Antimitotic) Derm: alopecia. Gi: diarrhea, nausea, vomiting, abdominal pain. Hemat: agranulocytosis, aplastic anemia, leukopenia, thrombocytopenia. Neuro: peripheral neuritis. Drug Class Antigout Agents Nursing Interventions Monitor intake and output ratios. Fluids should be encouraged to promote a urinary output of at least 2000 mL/day. Interactions Drug-Drug: Concurrent use of strong CYP3A4 inhibitors, including atazanavir, clarithromycin, etc. and risk of toxicity; colchicine dose in patients with normal renal or hepatic function; concurrent use in patients with renal or hepatic impairment is contraindicated. Client Education Evaluation of Medication Effectiveness Decrease in pain and swelling in affected joints within 12 hr. Relief of symptoms within 24– 48 hr. Prevention of acute gout attacks. Reduced number of attacks of familial Mediterranean fever. © 2021 Chamberlain University. All Rights Reserved Instruct patient to take colchicine as directed. Review medication administration schedule. Take missed doses as soon as remembered unless almost time for next dose. Name: Description: ...
User generated content is uploaded by users for the purposes of learning and should be used following Studypool's honor code & terms of service.
Studypool
4.7
Trustpilot
4.5
Sitejabber
4.4